Colesevelam plus rosuvastatin 5 mg/Day versus rosuvastatin 10 mg/Day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose

Metabolic Syndrome and Related Disorders

Volumn 11, Issue 3, 2013, Pages 152-156

  Florentin, Matilda ^a   Liberopoulos, Evangelos N ^a   Rizos, Christos V ^a   Kei, Anastazia A ^a   Liamis, George ^a   Kostapanos, Michael S ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLESEVELAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FLUOROBENZENES; GLUCOSE INTOLERANCE; HUMANS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDIABETIC STATE; PYRIMIDINES; SULFONAMIDES;

EID: 84877859008     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2012.0103     Document Type: Article

References (27)

1. Stratton IM, Adler AI, Neil HA, et al. Association of gly-caemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
2. Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7:211-228.
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
4. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 2009;32:1924-1929.
5. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
6. Kostapanos MS, Milionis HJ, Agouridis AD, et al. Rosu-vastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009;63:1308-1313.
7. Florentin M, Liberopoulos EN, Mikhailidis DP, et al. Cole-sevelam hydrochloride in clinical practice: A new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008;24:995-1009.
8. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on gly-cemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83.
9. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol 2010;59:198-205.
10. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, sim-vastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160.
11. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
12. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-2564.
13. Bays HE, Goldberg RB, Truitt KE, et al. Colesevelam hy-drochloride therapy in patients with type 2 diabetes mellitus treated with metformin: Glucose and lipid effects. Arch Intern Med 2008;168:1975-1983.
14. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484.
15. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mel-litus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-1540.
16. Rigby SP, Handelsman Y, Lai YL, et al. Effects of coleseve-lam HCl, rosiglitazone, or sitagliptin on glycemic control and the lipid profile in subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Endocr Pract 2010;16:53-63.
17. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. En-docr Pract 2009;15:540-559.
18. Handelsman Y, Goldberg RB, Garvey WT, et al. Coleseve-lam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: A randomized, prospective study. Endocr Pract 2010;16:617-628.
19. Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hy-drochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol 2011;108:1129-1135.
20. Claudl T, Staels B, Kuipers F. The Farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020-2030.
21. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997;272:3137-3140.
22. Cariou B, Duran-Sandoval D, Kuipers F, et al. Farnesoid X receptor: A new player in glucose metabolism? Endocrinology 2005;146:981-983.
23. Insull W, Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review. South Med J 2006;99:257-273.
24. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: A review. Expert Opin Pharmac-other 2007;8:2569-2578.
25. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17(Suppl 2):1-53.
26. McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001;24:460-464.
27. Rifkind BM. The Lipid Research Clinics Coronary Primary Prevention Trial. Drugs 1986;31(Suppl 1):53-60.